Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 1.00 |
| ▸ | CCR5 | P51681 | 2/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 6/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257584 | 1.00 | CCR2 (1.00) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL16257517 | 1.00 | CCR2 (1.00) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL16257551 | 1.00 | CCR2 (1.00) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL12179965 | 0.91 | CCR2 (0.84) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL12179972 | 0.91 | CCR2 (0.84) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL16257569 | 0.90 | CCR2 (0.81) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL16257571 | 0.90 | CCR2 (0.81) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL16257595 | 0.89 | CCR2 (0.79) | CCR2CCR5EGFRKCNH2 | |
| SCHEMBL16257522 | 0.89 | CCR2 (0.80) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL16257523 | 0.89 | CCR2 (0.80) | CCR2CCR5EPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946218-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2569295-B1 | NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |